115 related articles for article (PubMed ID: 18482097)
1. GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer.
Atack JR
CNS Neurosci Ther; 2008; 14(1):25-35. PubMed ID: 18482097
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of C-14 labeled GABA
Artelsmair M; Gu C; Lewis RJ; Elmore CS
J Labelled Comp Radiopharm; 2018 May; 61(5):415-426. PubMed ID: 29314165
[TBL] [Abstract][Full Text] [Related]
3. Improved Synthesis of Anxiolytic, Anticonvulsant and Antinociceptive α2/α3-GABA(A)ergic Receptor Subtype Selective Ligands as Promising Agents to Treat Anxiety, Epilepsy, as well as Neuropathic Pain.
Li G; Golani LK; Jahan R; Rashid F; Cook JM
Synthesis (Stuttg); 2018 Oct; 50(20):4124-4132. PubMed ID: 32773890
[TBL] [Abstract][Full Text] [Related]
4. The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.
de Haas SL; Zoethout RW; Van Dyck K; De Smet M; Rosen LB; Murphy MG; Gottesdiener KM; Schoemaker RC; Cohen AF; van Gerven JM
J Psychopharmacol; 2012 Feb; 26(2):282-91. PubMed ID: 21890585
[TBL] [Abstract][Full Text] [Related]
5. GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics.
Atack JR
Curr Top Med Chem; 2011; 11(9):1176-202. PubMed ID: 21050172
[TBL] [Abstract][Full Text] [Related]
6. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics.
Atack JR
Curr Top Behav Neurosci; 2010; 2():331-60. PubMed ID: 21309116
[TBL] [Abstract][Full Text] [Related]
7. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
[TBL] [Abstract][Full Text] [Related]
8. Global consensus statement on menopausal hormone therapy.
de Villiers TJ; Gass ML; Haines CJ; Hall JE; Lobo RA; Pierroz DD; Rees M
Climacteric; 2013 Apr; 16(2):203-4. PubMed ID: 23488524
[TBL] [Abstract][Full Text] [Related]
9. Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk.
Hilakivi-Clarke L; de Assis S; Warri A
J Mammary Gland Biol Neoplasia; 2013 Mar; 18(1):25-42. PubMed ID: 23392570
[TBL] [Abstract][Full Text] [Related]
10. Long term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J; Farquhar C; Roberts H; Lethaby A
Cochrane Database Syst Rev; 2012 Jul; (7):CD004143. PubMed ID: 22786488
[TBL] [Abstract][Full Text] [Related]
11. Hormone therapy and breast cancer risk 10 years after the WHI.
Gompel A; Santen RJ
Climacteric; 2012 Jun; 15(3):241-9. PubMed ID: 22612610
[TBL] [Abstract][Full Text] [Related]
12. HRT misuse and the osteoporosis epidemic.
Gambacciani M
Climacteric; 2012 Feb; 15(1):10-1. PubMed ID: 22132704
[TBL] [Abstract][Full Text] [Related]
13. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes.
Harman SM; Vittinghoff E; Brinton EA; Budoff MJ; Cedars MI; Lobo RA; Merriam GR; Miller VM; Naftolin F; Pal L; Santoro N; Taylor HS; Black DM
Am J Med; 2011 Mar; 124(3):199-205. PubMed ID: 21396500
[TBL] [Abstract][Full Text] [Related]
14. GABA
Masiulis S; Desai R; Uchański T; Serna Martin I; Laverty D; Karia D; Malinauskas T; Zivanov J; Pardon E; Kotecha A; Steyaert J; Miller KW; Aricescu AR
Nature; 2019 Jan; 565(7740):454-459. PubMed ID: 30602790
[TBL] [Abstract][Full Text] [Related]
15. The Case for Clinical Trials with Novel GABAergic Drugs in Diabetes Mellitus and Obesity.
Antoni FA
Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207609
[TBL] [Abstract][Full Text] [Related]
16. GABA
Belelli D; Hales TG; Lambert JJ; Luscher B; Olsen R; Peters JA; Rudolph U; Sieghart W
IUPHAR BPS Guide Pharm CITE; 2021 Sep; 2021(3):. PubMed ID: 35005623
[TBL] [Abstract][Full Text] [Related]
17. GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABA
Cerne R; Lippa A; Poe MM; Smith JL; Jin X; Ping X; Golani LK; Cook JM; Witkin JM
Pharmacol Ther; 2022 Jun; 234():108035. PubMed ID: 34793859
[TBL] [Abstract][Full Text] [Related]
18. Rational approaches for the design of various GABA modulators and their clinical progression.
Bhagat K; Singh JV; Pagare PP; Kumar N; Sharma A; Kaur G; Kinarivala N; Gandu S; Singh H; Sharma S; Bedi PMS
Mol Divers; 2021 Feb; 25(1):551-601. PubMed ID: 32170466
[TBL] [Abstract][Full Text] [Related]
19. Valium without dependence? Individual GABA
Cheng T; Wallace DM; Ponteri B; Tuli M
Neuropsychiatr Dis Treat; 2018; 14():1351-1361. PubMed ID: 29872302
[TBL] [Abstract][Full Text] [Related]
20. The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels.
Alexander SP; Benson HE; Faccenda E; Pawson AJ; Sharman JL; Spedding M; Peters JA; Harmar AJ;
Br J Pharmacol; 2013 Dec; 170(8):1582-606. PubMed ID: 24528238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
